RxDoctor Payments Data

Spencer Stoddard

Psychiatric/Mental Health · Lincoln, NENPI 1417645193

Payments from drug & device makers

$2,610in general payments, 2019–2025

Across 149 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$572
  • Otsuka America Pharmaceutical, Inc.$377
  • Axsome Therapeutics, Inc.$371
  • E.r. Squibb & Sons, L.L.C.$284
  • Jazz Pharmaceuticals Inc.$251
  • Alkermes, Inc.$195
  • plus $561 from 10 others

What the payments were for

  • Food & beverage$2,610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,610 in reported general payments places this provider in the 70th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$34,321
Medicare patients
62
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil39$140,120
Invega SustennaPaliperidone Palmitate29$96,723
VraylarCariprazine Hcl48$77,689
CaplytaLumateperone Tosylate30$43,852
Modafinil12$6,429
VyvanseLisdexamfetamine Dimesylate15$5,727
Lisdexamfetamine Dimesylate17$4,294
Aripiprazole96$3,722
Desvenlafaxine Succinate ErDesvenlafaxine Succinate50$2,937
Quetiapine Fumarate105$2,661
Paliperidone ErPaliperidone20$2,575
Bupropion XlBupropion Hcl81$1,873
Atomoxetine Hcl16$1,846
Escitalopram Oxalate39$1,561
Divalproex Sodium ErDivalproex Sodium50$1,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada$195$140,12039 claims
Johnson & JohnsonInvega Sustenna$136$96,72329 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$572$43,85230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →